Allergan PLC (AGN) Trading Down 2.8% After Price Target Decrease
Allergan PLC (NYSE:AGN) fell 2.8% during mid-day trading on Wednesday after Mizuho lowered their price target on the stock from $305.00 to $299.00. Mizuho currently has a buy rating on the stock. Allergan PLC traded as low as $229.33 and last traded at $231.30, with a volume of 3,369,448 shares changing hands. The stock had previously closed at $237.95.
A number of other research analysts have also weighed in on AGN. Piper Jaffray Cos. reissued a “hold” rating and issued a $236.00 target price on shares of Allergan PLC in a report on Saturday, June 18th. RBC Capital Markets reissued an “outperform” rating and issued a $300.00 target price (down from $307.00) on shares of Allergan PLC in a report on Wednesday, August 10th. Deutsche Bank AG cut their target price on shares of Allergan PLC from $282.00 to $278.00 and set a “buy” rating for the company in a report on Tuesday, August 9th. Morgan Stanley reissued an “overweight” rating on shares of Allergan PLC in a report on Wednesday, June 29th. Finally, Royal Bank Of Canada cut their target price on shares of Allergan PLC from $307.00 to $300.00 and set an “outperform” rating for the company in a report on Tuesday, August 9th. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $302.23.
Institutional investors have recently bought and sold shares of the stock. Veritas Asset Management LLP bought a new position in Allergan PLC during the second quarter valued at about $492,177,000. Emerald Acquisition Ltd. bought a new position in Allergan PLC during the second quarter valued at about $231,671,000. Appaloosa LP raised its position in Allergan PLC by 351.7% in the second quarter. Appaloosa LP now owns 1,260,809 shares of the company’s stock valued at $291,360,000 after buying an additional 981,700 shares during the period. Thornburg Investment Management Inc. raised its position in Allergan PLC by 133.2% in the second quarter. Thornburg Investment Management Inc. now owns 1,717,844 shares of the company’s stock valued at $396,977,000 after buying an additional 981,355 shares during the period. Finally, Eaton Vance Management raised its position in Allergan PLC by 112.8% in the second quarter. Eaton Vance Management now owns 1,713,711 shares of the company’s stock valued at $396,021,000 after buying an additional 908,569 shares during the period. Institutional investors own 85.19% of the company’s stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/allergan-plc-agn-trading-down-2-8-after-analyst-downgrade.html
The stock’s 50-day moving average is $239.23 and its 200-day moving average is $238.48. The company has a market cap of $91.79 billion, a P/E ratio of 22.07 and a beta of 0.81.
Allergan PLC (NYSE:AGN) last issued its earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The company earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the business earned $4.41 EPS. Equities research analysts expect that Allergan PLC will post $14.00 EPS for the current fiscal year.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.